CoChat

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

Open access
Frega, Giorgio, Wu, Qi, Le Naour, Julie, Vacchelli, Erika, Galluzzi, Lorenzo, Kroemer, Guido, Kepp, Oliver · 2020 · OncoImmunology

The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.

Abstract

Resiquimod (R848) and motolimod (VTX-2337) are second-generation experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory properties originally approved by the US Food and Drug Administration for the topical treatment of actinic keratosis and genital warts more than 20 years ago. Both resiquimod and motolimod operate as agonists of Toll-like receptor 7 (TLR7) and/or TLR8, in thus far delivering adjuvant-like signals to antigen-presenting cells (APCs). In line with such an activity, these compounds are currently investigated as immunostimulatory agents for the treatment of various malignancies, especially in combination with peptide-based, dendritic cell-based, cancer cell lysate-based, or DNA-based vaccines. Here, we summarize preclinical and clinical evidence recently collected to support the development of resiquimod and motolimod and other TLR7/TLR8 agonists as anticancer agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2020.1796002

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Current obstacles against the development of efficacious TLR7/TLR8 agonists for cancer therapy. Besides being hampered by specificity issues, the translation of currently available TLR7/TLR8 agonists to the clinic is limited by incomplete data on optimal delivery routes and administration schedules, as well as by the intrinsic issues associated with therapeutic cancer vaccines.
Figure 1. Current obstacles against the development of efficacious TLR7/TLR8 agonists for cancer therapy. Besides being hampered by specificity issues, the translation of currently available TLR7/TLR8 agonists to the clinic is limited by incomplete data on optimal delivery routes and administration schedules, as well as by the intrinsic issues associated with therapeutic cancer vaccines.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 147 references

Cited by

See all 108

Metadata

Authors
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O.
Affiliations
  • Inserm (FR)
  • Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers
  • Université Paris Cité (FR)
  • Karolinska University Hospital (SE)
Corresponding author
  • Kroemer, Guido
  • Kepp, Oliver
Venue
OncoImmunology
Published
2020-01
Volume
9
Issue
1
Pages
1796002-1796002
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W3045299854
Cited by
108
References
147
Citations by year
2026: 10 · 2025: 18 · 2024: 16 · 2023: 20 · 2022: 19 · 2021: 24 · 2020: 1
FWCI
1.56
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • U.S. Department of Defense (#BC180476P1)
  • Leukemia and Lymphoma Society
  • Association pour la Recherche sur le Cancer (ANR-18-IDEX-0001)
  • Seerave Foundation (ANR-18-IDEX-0001)
  • E-Rare
  • European Commission
  • Agence Nationale de la Recherche (ANR-18-IDEX-0001)
  • Fondation Leducq
  • Institut National de la Santé et de la Recherche Médicale (UMS3655, ANR-18-IDEX-0001)
  • Fondation pour la Recherche Médicale (ANR-18-IDEX-0001)
  • Ligue Contre le Cancer (ANR-18-IDEX-0001)
  • Centre National de la Recherche Scientifique (#ANR-18-IDEX-0001, UMS3655)
  • Institut Universitaire de France (ANR-18-IDEX-0001)
  • Institut National Du Cancer (#ANR-18-IDEX-0001)
  • Institut Gustave-Roussy (UMS3655)
  • European Research Area Network on Cardiovascular Diseases
  • Weill Cornell Medical College
  • Stand Up To Cancer (ZP-6177)
  • High-end Foreign Experts Recruitment Plan of China (GDW20171100085)
  • Labex Immuno-Oncology ((ANR-18-IDEX-0001))
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
resiquimod, imidazoquinolines, TLR agonists, cancer immunotherapy, adjuvants, dendritic cell vaccine, DNA vaccine, peptide vaccine, preclinical and clinical trials
MeSH terms
Imiquimod, Adjuvants, Immunologic, Antineoplastic Agents, United States, Toll-Like Receptor 7, Toll-Like Receptor 8

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. https://app.cochat.ai/papers/10.1080/2162402x.2020.1796002
The paper
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020). Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. OncoImmunology. https://doi.org/10.1080/2162402x.2020.1796002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.